Table 1.

Clinical information for patients involved in this study

Sample	Group	Age (years)	Sex	Race	Disease type	ILD/PAH	Disease duration (years)	ANA pattern	ANA titer	MRSS
SSc 1	TOP1	36	F	White	Diffuse	mild ILD	2.5		1:320	43
SSc 132	TOP1	49	F	White	Diffuse	No		Homogeneous	1:640	27
SSc 218	TOP1	55	F	White	Diffuse	ILD		Homogeneous/nucleolar	1:2560	18
SSc 208	TOP1	64	M	White	Diffuse	No		Nucleolar	1:1280	37
SSc 5	RNAP3	53	M	White	Diffuse	No	0.75	Speckled	1:80	36
SSc 7	RNAP3	45	F	Black	Diffuse	No	0.5	Speckled	1:80	27
SSc 10	RNAP3	52	M	White	Diffuse	No	0.5		0	22
SSc 18	RNAP3	69	F	White	Diffuse	ILD	0.5	Nucleolar	1:160	44
SSc 159	CENP	54	F	Mixed	Limited	No	7	Centromere	1:1280	2
SSc 177	CENP	64	F	White	Limited	No	15	Discrete speckled	4+
SSc 194	CENP	66	F	White	Limited	No	18	Discrete speckled	4+	6
SSc 238	CENP	53	F	White	Limited	No	6	Centromere	1:640	5
SSc 226	CENP	55	F	Asian	Diffuse	No		Centromere	1:1280	6
HC 162	Control	24	M	White
HC 400	Control	21	M	White
HC 117	Control		M
HC 118	Control		M

Blank cells indicate information not available at the time of sample collection. ILD interstitial lung disease, PAH pulmonary arterial hypertension, ANA anti-nuclear antibody, MRSS modified Rodnan skin score, SSc systemic sclerosis, M male, F female